Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 211 to 220 of 2557

TitleReference numberPublishedLast updated
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancerTA1041
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA1042
Advanced breast cancer: diagnosis and treatmentCG81
Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and overTA1038
Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and overTA1039
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapyTA1040
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and overTA1033
Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessmentHTG696
Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary interventionHTG740
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatmentTA1036

Results per page

  1. 10
  2. 25
  3. 50
  4. All